Cell-mediated immunity has been shown to be clinically important in recovery from herpes simplex virus (HSV) infections. To investigate the role of delayed hypersensitivity (DH) in immunity and protection against HSV, we developed a murine model using the ear-swelling assay. Mice were infected subcutaneously with HSV-1 and ear-challenged, and the swelling was quantified. Significant ear swelling was detected by 3 to 4 days postinfection and peaked at 6 days. The kinetics of development of ear swelling were typical of DH: maximal swelling occurred 24 h post challenge and was diminished by 48 h, and the cellular infiltrate was predominantly mononuclear. Four-hour swelling, indicative of antibodymediated, immediate-type hypersensitivity, was not detected until 15 days post immunization. The DH response was virus specific and could be transferred to normal recipients with lymph node T cells, but not with B cells or immune serum. This system will provide a useful model for evaluating the protective role of DH in HSV infection and for studying the specificity and interaction of T cells which mediate the response.
Exposure to a complex antigen, such as a virus, stimulates a variety of immune responses involving various subpopulations of cells. The relative effectiveness of each type of response in protecting the host from infections is dependent on the nature of the particular virus. With the increasing ability to assay separately for different immune mechanisms, it has become possible to examine which responses are triggered and which play a protective role in infection with a given pathogen.
We chose to study the delayed hypersensitivity (DH) response to herpes simplex virus (HSV) to examine the role of this response in protection from virus infection. Little is known specifically about DH to HSV, although the importance of cell-mediated immunity in host defense against HSV is well established. For example, individuals with depressed cell-mediated immunity due to immunosuppressive drugs or immunodeficiency disease often develop HSV infections, especially if they were previously susceptible to recrudescent infections (1, 13, 15, 23, 24) . In general, these individuals maintain high levels of neutralizing antibody to HSV which do not seem to afford a protective effect. Similar findings have been made in experimental animals. Transfer of HSV-immune T cells prevents death in HSV-infected adult thymectomized mice (7) , normal mice (3), nude mice (16) , and mice treated with anti-T lymphocyte serum (18) . Drugs and treatments which suppress cell-mediated immunity can increase reactivation of latent virus (19) . Also, HSV-specific cytotoxic T cells (Tc) are induced in HSV-infected mice, although this generally requires manipulation of the host with drugs to eliminate suppressor cells (10, 20) . Thus, although macrophages (22) , natural killer cells (2) , and antibody (16) have also been shown to play roles, it seems clear that T cells are important and perhaps obligatory for immune protection against HSV infections. In this report we describe the basic parameters of induction and elicitation of DH to HSV in mice. This basic system will be used in future experiments to investigate the role of DH effector cells in protection against primary and recrudescent HSV infections. MATERIALS As mentioned above, virus stocks were grown in both rabbit skin cells and 3T6. This procedure was used so that virus grown in one cell type could be used for immunization and the other could be used for challenge, thereby insuring that the immunity measured was to viral antigens and not to cellular components.
Transfer of DH. For transfer experiments, mice were immunized as above and the draining lymph nodes (inguinal, cervical, and brachial) were removed 4 days later. Single-cell suspensions were made by gently pushing the nodes through a 60-mesh wire screen. Cells were washed twice in Earle balanced salt solution (Colorado Serum Co., Denver, Colo.), and 50 x 106 lymph node cells (LNC) were injected intravenously in a volume of 0.5 ml. Recipient mice were ear challenged within 1 h of transfer, and ear swelling was measured after 24 h.
Antiserum. Anti-brain-associated 0 serum (anti-BA-0) was prepared in rabbits according to Golub (5) . Polyvalent rabbit anti-mouse immunoglobulin serum (anti-MIg) was prepared as previously described (25) . Before use, the sera were heat inactivated at 56°C and then adsorbed. Anti-BA-0 was adsorbed with normal mouse bone marrow and erythrocytes; anti-MIg was adsorbed with normal mouse thymocytes and erythrocytes. The cytotoxicity and specificity of both antisera have been described previously (14) . Lymph node cells (108 per ml) were suspended in 1:10 diluted antiserum, incubated for 1 h on ice, and washed with balanced salt solution. The cells were then suspended in 1:6 diluted guinea pig serum (108 cells/ml) and incubated for 5 min on ice followed by 40 min at 37°C.
After washing, the cells were suspended to 108 ml in balanced salt solution, and 0.5 ml was injected IV into each recipient.
Nylon-wool fractionation. Enrichment of lymph node T cells by passage through nylon wool was done using the method of Julius et al. (8) . Nonadherent cells were washed, suspended at 108/ml, and 0.5 ml was injected IV into each recipient. RESULTS Dose-response for immunization and challenge. To determine the optimal HSV dose for sensitization, groups of mice were immunized with a range of virus concentrations and ear challenged 6 days later. The results in Fig. 1 show that for immunization doses of 4 x 10' to 4 x 108 PFU/ mouse, the response was statistically on a plateau. When the immunization dose was lower than 4 x 105, the response dropped rapidly. A total of 4 x i05 PFU was used for immunization in all succeeding experiments.
The optimal challenge dose was determined by varying the number of PFU injected into the ears of mice immunized 6 days previously with 4 x 106 PFU of HSV. Table 1 shows a dosedependent increase in the ear swelling response to 106 PFU per ear, the maximum dose tested. In all subsequent experiments, 105 to 106 PFU per ear was used to elicit the DH response.
Histology of the mouse ears was also examined (data not shown). Ears from HSV-infected and control mice, 24 h after ear challenge, were fixed in buffered Formalin, sectioned, stained with hematoxylin-eosin, and examined under oil emersion at xlO0. Ears from the HSV-immune mice showed a uniform mononuclear cell infiltration characteristic of DH responses. In con- trast, ears from control mice had a very localized infiltrate which consisted almost entirely of polymorphonuclear cells.
Development of DH to HSV. To determine the kinetics of development of DH to HSV, mice were immunized on day 0, and individual groups were challenged on days 4, 6, 9, 12, and 15. Ear measurements were made at 4 and 24 h after challenge. Figure 2 demonstrates that the 24-h ear-swelling response was significant by day 4 (and on day 3, data not shown), peaked on day 6, and remained high at least through day 15 Ear swelling was measured 24 h after challenge.
able 24 h, but not 4 h, after ear challenge. Although the antibody-mediated (4-h) response was not apparent during the 6-day interval used in the assay, it was significant at 15 days. The DH response was shown to be mediated by T cells since anti-MIg-plus-complement-treated or nylon-wool nonadherent immune LNC could transfer DH to HSV, although anti-BA-0-treated cells or immune serum could not transfer immunity. Examination of the specificity of the response demonstrated that DH to HSV-1 was virus specific (no response to polyoma virus was seen in HSV-1-immunized mice), but not type specific, since mice immunized with HSV-1 responded significantly to challenge with HSV-2. The reciprocal experiment showed similar results, i.e., mice immunized with HSV-2 responded strongly to challenge with HSV-1 (data not shown). This reactivity probably reflects the considerable number of determinants shared by HSV-1 and HSV-2. These strains share 50% DNA homology (9), antibody to several of the glycoproteins of HSV-1 and HSV-2 cross-react (6, 21) , and peptide mapping has recently shown similar amino acid sequences in a corresponding HSV-1 and HSV-2 glycoprotein (G. Cohen, personal communication). However, in spite of the biochemical similarities between HSV-1 and HSV-2 and in contrast to antibody and DH crossreactivity it has been reported that HSV-specific Tc are able to distinguish between HSV-1-and HSV-2-infected target cells (20) . It is not known whether this difference in specificity is due to differences in virus preparations or strains or in vivo versus in vitro assays or whether the T-cellmediating DH and antibodies recognize typecommon determinants, whereas Tc detect unshared determinants on HSV-1 and HSV-2. Currently, little is known concerning which viral determinants are recognized in the DH response. Since HSV is a complex virus, express- IG. 4 . Ability of different cell populations to transfer DH to HSV. Mice were immunized with 4 x 106 PFU of HSV-1, and the draining lymph nodes were removed 4 days later. In experiment I, the immune LNC were treated with normal rabbit serum (NRS) plus complement (C'), anti-MIg plus complement, or anti-BA-0 + C' and transferred into normal recipients. A 0.4-ml amount of immune serum was also transferred. In experiment II, the immune LNC were either passed over a nylon-wool column and the nonadherent fraction was collected, or they were left unfractionated and injected into normal recipients. In both experiments, recipients were ear challenged with 10i (UV-inactivated) PFU of HSV within 1 h of transfer. Ear swelling was measured 24 h after challenge. (26) , DH to influenza virus appears to be highly cross-reactive among serotypes. Liew et al. (12) , immunizing with a detergent extract of type A influenza, and Leung and Ada (11), infecting with type A influenza virus, both report that DH is crossreactive for all A strain influenza.
Protection against HSV infections (either latent or primary) has long been considered to be primarily dependent on cellular mechanisms, although there is evidence that macrophages and natural killer cells may be important, especially in primary infections (2, 22) . Until recently, T cell subpopulations have not been examined separately. One report (7) showed that transfer of HSV-immune cells that shared K/D determinants of the major histocompatibility complex with the recipient strain gave transient protection from HSV infection, whereas immune cells sharing I region determinants with the recipient transferred long-term protection. H-2-incompatible cells gave no protection. Other reports (20) have shown that Tc to HSV are K/D restricted. Attempts to induce Tc to HSV have resulted in low levels of response, and development of significant Tc activity requires cyclophosphamide pretreatment of extended in vitro culture of the Tc before the assay (10, 20) . This difficulty in detecting Tc to HSV brings into question their in vivo significance in immunopotentiation. In contrast to the difficulty found in demonstrating Tc to HSV, DH was readily induced. Recently, Nash et al. (17) , also describing a DH response to HSV, found that transfer of HSV-immune T cells into normal recipients was able to reduce the local virus titer when virus was injected, indicating that T cells are capable of acting against HSV in vivo. The model system described here will be used to examine cell-mediated immunity to HSV, as measured by DH and to determine whether there is a correlation between the responsive state and protection against acute infection or establishment of latency by HSV.
